- Mar 27
- |
- 2025
Press Release
- Follow Us
Powered by Cutting-edge Platforms and Bench Expertise
We are passionate about cultivating enduring relationships with our clients, working to become a trusted partner in achieving their scientific and commercial goals.
Service Platforms
We leverage 5 key platforms to deliver groundbreaking proteomic services. The HuProt™ Human Proteome Microarray offers the most extensive collection of full-length, folded proteins available for whole proteome assays. Our PhIP-Seq platforms, HuScan®, MouseScan™ and VirScan®, enable epitope-level profiling against human and mouse proteomes, as well as most vertebrate viral proteomes. The VirD™ Functional Membrane Protein Microarray offers the capability to assay membrane-embedded functional proteins in a highly multiplexed format.
* Provided exclusively by CDI Labs Canada.
Seromics Services
Autoantibody seromics is the study of the autoantibody reactome, a complex network of interactions and effects driven by autoantibodies that mistakenly target the body’s own tissues. Autoantibodies can arise from inflammation, infections, or tissue damage, and play critical roles in autoimmune and non-autoimmune conditions, including neurological disorders, cancer, infectious diseases, genetic disorders, and cardiovascular issues. Our services enable proteome-wide autoantibody profiling with the HuProt™ Human Proteome Microarray, to assay binding to full-length folded proteins, and PhIP-Seq-based services such as HuScan® and MouseScan™ PhIP-Seq to assay epitope-level binding.
Target ID Services
Target identification is a vital step in drug discovery and development, focusing on pinpointing specific molecules or biological pathways critical to a disease process and suitable for therapeutic intervention. The HuProt™ Human Proteome Microarray and VirD™ Functional Membrane Protein Microarray are advanced tools for Target ID studies. HuProt enables researchers to analyze compound interactions with full-length, folded, human proteins at a proteome-wide scale, while VirD enables highly-multiplexed analysis of binding to membrane-embedded proteins.
Specialized CRO Services
We leverage cutting-edge synthetic biology platforms and an extensive proteome collection to provide specialized, tailored services. Supported by a team of experts, we empower clients to uncover molecular interactions across entire proteomes. Committed to fostering strong partnerships, we aim to be a reliable ally in helping clients achieve their scientific and commercial goals.
Disease Areas
We focus on advancing research in autoimmune diseases, neurological diseases, oncology, infectious diseases, genetic diseases and the study of aging with our cutting-edge services for proteome-wide autoantibody profiling and target identification. Our products, including the HuProt™ Human Proteome Microarray, the VirD™ Functional Membrane Protein Microarray, and PhIP-Seq-based services like VirScan®, HuScan®, and MouseScan™, empower researchers and drug developers to achieve breakthroughs across a wide spectrum of scientific fields.
The Most Comprehensive Portfolio and Content for Autoantibody Discovery and Target ID
Transformational products and services for proteome-wide autoantibody profiling, biomarker discovery, cross-reactivity screening, and other whole-proteome target identification and interaction assays
We Offer the Most Powerful Antigen Libraries
21,000+ Full-length Proteins
Correctly-folded, GST-purified recombinant proteins and isoform variants
All Human Proteome
Detects antibodies against 48,921 unique human proteins and protein isoforms
All Murine Proteome
Detects antibodies against 50,135 unique murine proteins and protein isoforms
VirScan, HuScan and MouseScan are provided exclusively by CDI Labs Canada.
PUBLICATION HIGHLIGHT
Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency
AUTHORS
ABSTRACT
Patients with autoimmune polyendocrinopathy syndrome type 1 (APS-1) caused by autosomal recessive AIRE deficiency produce autoantibodies that neutralize type I interferons (IFNs), conferring a predisposition to life-threatening COVID-19 pneumonia. Here we report that patients with autosomal recessive NIK or RELB deficiency, or a specific type of autosomal-dominant NF-κB2 deficiency, also have neutralizing autoantibodies against type I IFNs and are at higher risk of getting life-threatening COVID-19 pneumonia. In patients with autosomal-dominant NF-κB2 deficiency, these autoantibodies are found only in individuals who are heterozygous for variants associated with both transcription (p52 activity) loss of function (LOF) due to impaired p100 processing to generate p52, and regulatory (IκBδ activity) gain of function (GOF) due to the accumulation of unprocessed p100, therefore increasing the inhibitory activity of IκBδ (hereafter, p52LOF/IκBδGOF). By contrast, neutralizing autoantibodies against type I IFNs are not found in individuals who are heterozygous for NFKB2 variants causing haploinsufficiency of p100 and p52 (hereafter, p52LOF/IκBδLOF) or gain-of-function of p52 (hereafter, p52GOF/IκBδLOF). In contrast to patients with APS-1, patients with disorders of NIK, RELB or NF-κB2 have very few tissue-specific autoantibodies. However, their thymuses have an abnormal structure, with few AIRE-expressing medullary thymic epithelial cells. Human inborn errors of the alternative NF-κB pathway impair the development of AIRE-expressing medullary thymic epithelial cells, thereby underlying the production of autoantibodies against type I IFNs and predisposition to viral diseases.
More Content and Better Data
We start with sequence-confirmed plasmids, then individually express and GST-purify proteins from S. cerevisiae. Piezolelectric inkjet printing is used to spot these in duplicate alongside controls. Quality is confirmed with anti-GST QA/QC. Successful folding demonstrated by kinase autophosphorylation assay.
PUBLICATIONS
270+peer-reviewed publications
With over 270 publications (and growing), our antibody seromics solutions, HuProt microarray and PhIP-Seq continue to play a key role in life sciences by contributing to critical studies that help accelerate research, advance discoveries, and translate discoveries to novel products that improve human health.
CUSTOMER-BASE
190+customer base
Our customer base continues to expand throughout North America, Europe, and Asia Pacific, and is a testament to the quality and consistency of our products and services.
FOUNDERS
Boeke, Zhu & Blackshawat Johns Hopkins University
Funded by NIH Common Fund Support for the Development of Protein Capture Reagents and Technologies, the HuProt Protein Microarray was created by CDI Labs co-founders Jef Boeke, Heng Zhu, Dan Eichinger, and Seth Blackshaw, faculty members at the High Throughput Biology (HIT) Center at the Johns Hopkins University School of Medicine.